Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2024—Guardant Health announced FDA approval of the company’s Shield blood test for colorectal cancer screening in adults who are 45 and older and at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for CRC and that meets performance requirements for Medicare coverage.
August 2024—BioPorto Diagnostics unveiled its ProNephro AKI (NGAL) test at ADLM 2024, July 28–Aug. 1, in Chicago. The FDA 510(k)-cleared test is the first acute kidney injury biomarker test cleared for pediatric use (ages 3 months through 21 years) in the United States.
August 2024—Horiba announced that it has expanded its compact hematology instrument range with the launch of three models now with erythrocyte sedimentation rate onboard. The Yumizen H550E (autoloader), H500E CT (closed tube), and H500E OT (open tube) offer combined testing for CBC with differential and ESR results from whole blood in 60 seconds.
August 2024—Machaon Diagnostics has updated its genetic panel for detecting hemophagocytic lymphohistiocytosis. The HLH genetic panel 3.0 sequences 32 genes to reflect the most current understanding of HLH in the scientific literature and includes UNC13D inversion. The panel has a turnaround time of 48 hours. Draw kits are available.
August 2024—Bio-Rad Laboratories has launched its Exact Diagnostics GBS positive and negative run controls. The independent quality controls are intended to be used with group B streptococcus molecular assays for evaluating assay performance and testing operator proficiency.
August 2024—Sysmex America announced on July 9 that longtime health care executive Dan Zortman has been named the company’s new CEO. Andy Hay, who has served as CEO since 2021, will continue to serve as chairman and president of Sysmex America with a focus on the company’s emerging Hinotori surgical robotic system business.
August 2024—Qiagen has launched its QIAseq Multimodal DNA/RNA Lib Kit. The kit enables the preparation of DNA and RNA libraries for next-generation sequencing as well as downstream target enrichment based on hybrid capture from a single sample. It offers a streamlined and rapid workflow to generate whole genome and whole transcriptome sequencing libraries from a single sample by combining chemistry optimized for DNA and RNA simultaneously.
August 2024—Clarapath, a medical robotics company headquartered in Hawthorne, NY, announced it has entered into a strategic collaboration with Mayo Clinic to advance laboratory automation. Clarapath’s SectionStar is an all-in-one tissue sectioning and transfer system that is designed to increase capacity, reliability, and consistency while minimizing the need for highly skilled labor. The collaboration combines Clarapath’s tissue solution and domain experts with the clinical insights and expertise of the Mayo Clinic to enable laboratories to digitally transform the quality, safety, cost, and throughput of their histology process.
August 2024—Quest Diagnostics launched a blood biomarker test for phosphorylated tau 217, a biomarker associated with Alzheimer’s disease. It is the latest addition to Quest’s AD-Detect portfolio of tests, which also includes tests for p-tau181, amyloid beta proteins, and apolipoprotein E isoforms.
August 2024—Verichem Laboratories is now offering a multilevel, multianalyte, and ready-to-use Enzyme ER Calibration Verifier kit designed for the calibration verification of enzyme assays on wet chemistry testing systems. The enzyme components within the materials include amylase, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, cholinesterase, creatine phosphokinase, gamma-glutamyltransferase, lactate dehydrogenase, and lipase and are intended to be treated as patient specimens. The materials have a shelf life and open-vial stability of 18 months.
